Acquired long QT syndrome and torsade de pointes

@article{ElSherif2018AcquiredLQ,
  title={Acquired long QT syndrome and torsade de pointes},
  author={Nabil El-Sherif and Gioia Turitto and Mohamed Boutjdir},
  journal={Pacing and Clinical Electrophysiology},
  year={2018},
  volume={41},
  pages={414 - 421}
}
Since its initial description by Jervell and Lange‐Nielsen in 1957, the congenital long QT syndrome (LQTS) has been the most investigated cardiac ion channelopathy. Although congenital LQTS continues to remain the domain of cardiologists, cardiac electrophysiologists, and specialized centers, the by far more frequent acquired drug‐induced LQTS is the domain of all physicians and other members of the health care team who are required to make therapeutic decisions. This report will review the… Expand
Acquired Long QT Syndrome after Acute Myocardial Infarction: A Rare but Potentially Fatal Entity.
TLDR
Clinicians are reminded of this potentially fatal ventricular arrhythmia after myocardial infarction in a 58-year-old woman that had no clear cause and progressed to torsades de pointes requiring treatment with isoproterenol and magnesium. Expand
A CONGENITAL DEADLY ASSOCIATION: DILATED CARDIOMYOPATHY AND LONG QT SYNDROME
TLDR
An interesting case of this association between channelopathies and congenital cardiomyopathy is reported that maybe related to a genetic mutation. Expand
Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation
TLDR
There is considerable inter-individual variability in drug response, thus making the application of personalized medicine a relevant aspect in long QT syndrome, in order to evaluate the risk of every individual from a pharmacogenetic standpoint. Expand
Pathogenesis of Autoimmune-Associated Long QT Syndrome
TLDR
Current knowledge in the functional and molecular basis of autoantibody (anti-Ro/SSA antibodies)-induced QTc prolongation in patients with autoimmune diseases particularly connective tissue disease as well as in the general population subjects with torsades de pointes is discussed. Expand
Anaesthetic Challenges of a Patient Undergoing Left Cardiac Sympathetic Denervation in Therapy of Long QT Syndrome
TLDR
With careful preoperative preparation and by avoidance of factors that precipitate cardiac dysrhythmias during the peri operative period, patients can be safely anaesthetised for thoracic sympathectomy. Expand
Malignant Ventricular Arrhythmias Resulting From Drug-Induced QTc Prolongation: A Retrospective Study
TLDR
In some probably genetically predisposed subjects, the occurrence of symptoms and/or documented arrhythmic events (TdP, ventricular fibrillation) is related to intake of certain drugs (antiarrhythmics, antimicrobials such as quinolones and macrolides, etc.), Nevertheless, in diLQTc patients, QTc duration didn’t predict occurrence of Symptoms, or arrhythmmic events. Expand
Acquired drug-induced long QTc: new insights coming from a retrospective study
TLDR
In diLQTc patients, QTc duration did not predict occurrence of symptoms, or arrhythmic events, and other determinants should be postulated to clarify why sometimes diQTC prolongation propitiates ventricular malignant arrhythmias whereas in other cases this arrh rhythmogenic effect is lacking. Expand
Peculiar Aspects of Patients with Inherited Arrhythmias during the COVID-19 Pandemic.
TLDR
The aim of this review is to highlight the main challenges the authors may encounter during the Covid 19 pandemic, specifically in patients with hereditary arrhythmias, with emphasis on the congenital long QT syndrome (LQTS), Brugada syndrome (SBr), ventricular tachycardia polymorphic catecholaminergic (CPVT) and arrh rhythmogenic right ventricular cardiomyopathy. Expand
Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies
TLDR
A novel and more comprehensive classification of cardiac channelopathies is proposed, distinguishing the “classic” inherited forms, related to genetic mutations, from the more recently recognized autoimmune and inflammatory/flammatory forms. Expand
Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome
TLDR
Recent population data demonstrate that the risk of LQTS in subjects with circulating anti-Ro/SSA antibodies is significantly increased independent of a history of overt AD, intriguingly suggesting that these autoantibodies may silently contribute to a number of cases of ventricular arrhythmias and cardiac arrest in the general population. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 92 REFERENCES
The Long QT Syndrome and Torsade De Pointes
TLDR
Although it is difficult to predict which patients are at risk for TdP, careful assessment of the risk‐benefit ratio is important before prescribing drugs known to be able to cause QT prolongation, the continually unraveling molecular biology of congenital LQTS is discussed. Expand
Drug-Induced Long QT Syndrome
TLDR
This review will outline how defining the central mechanism, block of the cardiac delayed-rectifier potassium current IKr, has contributed to defining risk in patients and in populations. Expand
The long-QT syndrome.
  • W. Allan
  • Medicine
  • The New England journal of medicine
  • 2000
Post-acute management of the acquired long QT syndrome
TLDR
Considering the relatively high risk of arrhythmic recurrence in the highest risk ALQTS patients, effective preventive and treatment strategies are warranted, and further research is needed. Expand
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
TLDR
While European annual reporting rates based on spontaneous reports suggest an annual diLQTS/TdP incidence of 0.26 per million in Germany, an extrapolation of the Berlin incidence rates to the German Standard Population suggests a considerably higher incidence in an active surveillance approach. Expand
Efavirenz-Associated QT Prolongation and Torsade de Pointes Arrhythmia
TLDR
The first reported case of QT prolongation and severe ventricular arrhythmia associated with the use of efavirenz shows that any new pharmaceutical compound introduced in clinical practice may potentially result in QT prolongedation and life-threatening arrhythmias. Expand
Potassium Channel Block and Novel Autoimmune-Associated Long QT Syndrome.
TLDR
Advances in the pathogenesis of anti-SSA/Ro antibody-induced corrected QT (QTc) prolongation in patients with autoimmune diseases; particularly connective tissue disease (CTD) are reviewed. Expand
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
TLDR
Genetic linkage between LQT3 and polymorphisms within SCN5A, the cardiac sodium channel gene, and single strand conformation polymorphism and DNA sequence analyses suggest that mutations in SCN 5A cause chromosome 3-linked LQt and indicate a likely cellular mechanism for this disorder. Expand
Molecular mechanism for an inherited cardiac arrhythmia
TLDR
Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a molecular mechanism for this form of congenital long-QT syndrome. Expand
Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives
TLDR
A detailed characterization of the genetic substrate underlying congenital and drug-induced LQTS will enhance risk stratification and potentially result in the development of tailored genotype-based therapies. Expand
...
1
2
3
4
5
...